ABIONYX Pharma SA (EPA:ABNX)
1.678
-0.026 (-1.53%)
Nov 12, 2026, 9:58 AM CET
ABIONYX Pharma Stock Forecast
EPA-ABNX's stock price has decreased by -60.98% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, ABIONYX Pharma stock has a consensus rating of "Strong Buy" and an average price target of €9.75. The average 1-year stock price forecast is 481.05% higher than the current stock price, while the lowest is €8.50 (+406.56%) and the highest is €11.00 (+555.54%).
Price Target: €9.75 (+481.05%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ABIONYX Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | May '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 2 |
Financial Forecast
Revenue This Year
4.15M
from 4.06M
Increased by 2.14%
Revenue Next Year
4.20M
from 4.15M
Increased by 1.20%
EPS This Year
-0.24
from -0.16
EPS Next Year
-0.34
from -0.24
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.